The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to offer a significant substantial reduction in body weight and enhance metabolic